Bill Text: IL SB2089 | 2023-2024 | 103rd General Assembly | Introduced

---

Bill Title: Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced) 2024-03-15 - Rule 3-9(a) / Re-referred to Assignments [SB2089 Detail]

Download: Illinois-2023-SB2089-Introduced.html

---

103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB2089 Introduced 2/9/2023, by Sen. Patrick J. Joyce SYNOPSIS AS INTRODUCED:
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/401 from Ch. 56 1/2, par. 1401
Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine.
LRB103 27669 RLC 57233 b
A BILL FOR
SB2089 LRB103 27669 RLC 57233 b
AN ACT concerning criminal law.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Illinois Controlled Substances Act is
amended by changing Sections 204 and 401 as follows:
(720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
Sec. 204. (a) The controlled substances listed in this
Section are included in Schedule I.
(b) Unless specifically excepted or unless listed in
another schedule, any of the following opiates, including
their isomers, esters, ethers, salts, and salts of isomers,
esters, and ethers, whenever the existence of such isomers,
esters, ethers and salts is possible within the specific
chemical designation:
(1) Acetylmethadol;
(1.1) Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl)-
4-piperidinyl]-N-phenylacetamide);
(2) Allylprodine;
(3) Alphacetylmethadol, except
levo-alphacetylmethadol (also known as levo-alpha-
acetylmethadol, levomethadyl acetate, or LAAM);
(4) Alphameprodine;

SB2089 - 2 - LRB103 27669 RLC 57233 b
(5) Alphamethadol;
(6) Alpha-methylfentanyl
(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
propanilido) piperidine;
(6.1) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl)ethyl-
4-piperidinyl]-N-phenylpropanamide);
(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
(7.1) PEPAP
(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(8) Benzethidine;
(9) Betacetylmethadol;
(9.1) Beta-hydroxyfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-
4-piperidinyl]-N-phenylpropanamide);
(10) Betameprodine;
(11) Betamethadol;
(12) Betaprodine;
(13) Clonitazene;
(14) Dextromoramide;
(15) Diampromide;
(16) Diethylthiambutene;
(17) Difenoxin;
(18) Dimenoxadol;
(19) Dimepheptanol;

SB2089 - 3 - LRB103 27669 RLC 57233 b
(20) Dimethylthiambutene;
(21) Dioxaphetylbutyrate;
(22) Dipipanone;
(23) Ethylmethylthiambutene;
(24) Etonitazene;
(25) Etoxeridine;
(26) Furethidine;
(27) Hydroxpethidine;
(28) Ketobemidone;
(29) Levomoramide;
(30) Levophenacylmorphan;
(31) 3-Methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-
4-piperidyl]-N-phenylpropanamide);
(31.1) 3-Methylthiofentanyl
(N-[(3-methyl-1-(2-thienyl)ethyl-
4-piperidinyl]-N-phenylpropanamide);
(32) Morpheridine;
(33) Noracymethadol;
(34) Norlevorphanol;
(35) Normethadone;
(36) Norpipanone;
(36.1) Para-fluorofentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
4-piperidinyl]propanamide);
(37) Phenadoxone;

SB2089 - 4 - LRB103 27669 RLC 57233 b
(38) Phenampromide;
(39) Phenomorphan;
(40) Phenoperidine;
(41) Piritramide;
(42) Proheptazine;
(43) Properidine;
(44) Propiram;
(45) Racemoramide;
(45.1) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl-
4-piperidinyl]-propanamide);
(46) Tilidine;
(47) Trimeperidine;
(48) Beta-hydroxy-3-methylfentanyl (other name:
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
N-phenylpropanamide);
(49) Furanyl fentanyl (FU-F);
(50) Butyryl fentanyl;
(51) Valeryl fentanyl;
(52) Acetyl fentanyl;
(53) Beta-hydroxy-thiofentanyl;
(54) 3,4-dichloro-N-[2-
(dimethylamino)cyclohexyl]-N-
methylbenzamide (U-47700);
(55) 4-chloro-N-[1-[2-
(4-nitrophenyl)ethyl]-2-piperidinylidene]-

SB2089 - 5 - LRB103 27669 RLC 57233 b
benzenesulfonamide (W-18);
(56) 4-chloro-N-[1-(2-phenylethyl)
-2-piperidinylidene]-benzenesulfonamide (W-15);
(57) acrylfentanyl (acryloylfentanyl).
(c) Unless specifically excepted or unless listed in
another schedule, any of the following opium derivatives, its
salts, isomers and salts of isomers, whenever the existence of
such salts, isomers and salts of isomers is possible within
the specific chemical designation:
(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Diacetyldihydromorphine (Dihydroheroin);
(9) Dihydromorphine;
(10) Drotebanol;
(11) Etorphine (except hydrochloride salt);
(12) Heroin;
(13) Hydromorphinol;
(14) Methyldesorphine;
(15) Methyldihydromorphine;
(16) Morphine methylbromide;
(17) Morphine methylsulfonate;

SB2089 - 6 - LRB103 27669 RLC 57233 b
(18) Morphine-N-Oxide;
(19) Myrophine;
(20) Nicocodeine;
(21) Nicomorphine;
(22) Normorphine;
(23) Pholcodine;
(24) Thebacon.
(d) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
hallucinogenic substances, or which contains any of its salts,
isomers and salts of isomers, whenever the existence of such
salts, isomers, and salts of isomers is possible within the
specific chemical designation (for the purposes of this
paragraph only, the term "isomer" includes the optical,
position and geometric isomers):
(1) 3,4-methylenedioxyamphetamine
(alpha-methyl,3,4-methylenedioxyphenethylamine,
methylenedioxyamphetamine, MDA);
(1.1) Alpha-ethyltryptamine
(some trade or other names: etryptamine;
MONASE; alpha-ethyl-1H-indole-3-ethanamine;
3-(2-aminobutyl)indole; a-ET; and AET);
(2) 3,4-methylenedioxymethamphetamine (MDMA);
(2.1) 3,4-methylenedioxy-N-ethylamphetamine
(also known as: N-ethyl-alpha-methyl-

SB2089 - 7 - LRB103 27669 RLC 57233 b
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
and MDEA);
(2.2) N-Benzylpiperazine (BZP);
(2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
(4) 3,4,5-trimethoxyamphetamine (TMA);
(5) (Blank);
(6) Diethyltryptamine (DET);
(7) Dimethyltryptamine (DMT);
(7.1) 5-Methoxy-diallyltryptamine;
(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
(9) Ibogaine (some trade and other names:
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
indole; Tabernanthe iboga);
(10) Lysergic acid diethylamide;
(10.1) Salvinorin A;
(10.5) Salvia divinorum (meaning all parts of the
plant presently classified botanically as Salvia
divinorum, whether growing or not, the seeds thereof, any
extract from any part of that plant, and every compound,
manufacture, salts, isomers, and salts of isomers whenever
the existence of such salts, isomers, and salts of isomers
is possible within the specific chemical designation,
derivative, mixture, or preparation of that plant, its
seeds or extracts);

SB2089 - 8 - LRB103 27669 RLC 57233 b
(11) 3,4,5-trimethoxyphenethylamine (Mescaline);
(12) Peyote (meaning all parts of the plant presently
classified botanically as Lophophora williamsii Lemaire,
whether growing or not, the seeds thereof, any extract
from any part of that plant, and every compound,
manufacture, salts, derivative, mixture, or preparation of
that plant, its seeds or extracts);
(13) N-ethyl-3-piperidyl benzilate (JB 318);
(14) N-methyl-3-piperidyl benzilate;
(14.1) N-hydroxy-3,4-methylenedioxyamphetamine
(also known as N-hydroxy-alpha-methyl-
3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
(15) Parahexyl; some trade or other names:
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
dibenzo (b,d) pyran; Synhexyl;
(16) Psilocybin;
(17) Psilocyn;
(18) Alpha-methyltryptamine (AMT);
(19) 2,5-dimethoxyamphetamine
(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
(20) 4-bromo-2,5-dimethoxyamphetamine
(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
4-bromo-2,5-DMA);
(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
Some trade or other names: 2-(4-bromo-
2,5-dimethoxyphenyl)-1-aminoethane;

SB2089 - 9 - LRB103 27669 RLC 57233 b
alpha-desmethyl DOB, 2CB, Nexus;
(21) 4-methoxyamphetamine
(4-methoxy-alpha-methylphenethylamine;
paramethoxyamphetamine; PMA);
(22) (Blank);
(23) Ethylamine analog of phencyclidine.
Some trade or other names:
N-ethyl-1-phenylcyclohexylamine,
(1-phenylcyclohexyl) ethylamine,
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
(24) Pyrrolidine analog of phencyclidine. Some trade
or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
PHP;
(25) 5-methoxy-3,4-methylenedioxy-amphetamine;
(26) 2,5-dimethoxy-4-ethylamphetamine
(another name: DOET);
(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
(another name: TCPy);
(28) (Blank);
(29) Thiophene analog of phencyclidine (some trade
or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
2-thienyl analog of phencyclidine; TPCP; TCP);
(29.1) Benzothiophene analog of phencyclidine. Some
trade or other names: BTCP or benocyclidine;
(29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
(30) Bufotenine (some trade or other names:

SB2089 - 10 - LRB103 27669 RLC 57233 b
3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
3-(2-dimethylaminoethyl)-5-indolol;
5-hydroxy-N,N-dimethyltryptamine;
N,N-dimethylserotonin; mappine);
(31) (Blank);
(32) (Blank);
(33) (Blank);
(34) (Blank);
(34.5) (Blank);
(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
(2-methyloctan-2-yl)-6a,7,
10,10a-tetrahydrobenzo[c]chromen-1-ol
Some trade or other names: HU-210;
(35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
tetrahydrobenzo[c]chromen-1-ol, its isomers,
salts, and salts of isomers; Some trade or other
names: HU-210, Dexanabinol;
(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
6,6-dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
Some trade or other names: HU-211;
(37) (Blank);
(38) (Blank);
(39) (Blank);
(40) (Blank);

SB2089 - 11 - LRB103 27669 RLC 57233 b
(41) (Blank);
(42) Any compound structurally derived from
3-(1-naphthoyl)indole or
1H-indol-3-yl-(1-naphthyl)methane by substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl whether or not further substituted
in the indole ring to any extent, whether or not
substituted in the naphthyl ring to any extent. Examples
of this structural class include, but are not limited to,
JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
(43) Any compound structurally derived from
3-(1-naphthoyl)pyrrole by substitution at the nitrogen
atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
in the pyrrole ring to any extent, whether or not
substituted in the naphthyl ring to any extent. Examples
of this structural class include, but are not limited to,
JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
(44) Any compound structurally derived from
1-(1-naphthylmethyl)indene by substitution at the
3-position of the indene ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,

SB2089 - 12 - LRB103 27669 RLC 57233 b
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl whether or not further substituted
in the indene ring to any extent, whether or not
substituted in the naphthyl ring to any extent. Examples
of this structural class include, but are not limited to,
JWH-176;
(45) Any compound structurally derived from
3-phenylacetylindole by substitution at the nitrogen atom
of the indole ring with alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
in the indole ring to any extent, whether or not
substituted in the phenyl ring to any extent. Examples of
this structural class include, but are not limited to,
JWH-167, JWH-250, JWH-251, and RCS-8;
(46) Any compound structurally derived from
2-(3-hydroxycyclohexyl)phenol by substitution at the
5-position of the phenolic ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not substituted in the
cyclohexyl ring to any extent. Examples of this structural
class include, but are not limited to, CP 47, 497 and its
C8 homologue (cannabicyclohexanol);
(46.1) Any compound structurally derived from

SB2089 - 13 - LRB103 27669 RLC 57233 b
3-(benzoyl) indole with substitution at the nitrogen atom
of the indole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group whether or not further
substituted in the indole ring to any extent and whether
or not substituted in the phenyl ring to any extent.
Examples of this structural class include, but are not
limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
48,098), and RCS-4;
(47) (Blank);
(48) (Blank);
(49) (Blank);
(50) (Blank);
(51) (Blank);
(52) (Blank);
(53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
Some trade or other names: 2C-T-7;
(53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-E;
(53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
trade or other names: 2C-D;
(53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-C;
(53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
or other names: 2C-I;

SB2089 - 14 - LRB103 27669 RLC 57233 b
(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-T-2;
(53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
Some trade or other names: 2C-T-4;
(53.7) 2,5-dimethoxyphenethylamine. Some trade or
other names: 2C-H;
(53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
trade or other names: 2C-N;
(53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
trade or other names: 2C-P;
(53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
Some trade or other names: 2C-G;
(53.11) The N-(2-methoxybenzyl) derivative of any 2C
phenethylamine referred to in subparagraphs (20.1), (53),
(53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
(53.8), (53.9), and (53.10) including, but not limited to,
25I-NBOMe and 25C-NBOMe;
(54) 5-Methoxy-N,N-diisopropyltryptamine;
(55) (Blank);
(56) (Blank);
(57) (Blank);
(58) (Blank);
(59) 3-cyclopropoylindole with substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or

SB2089 - 15 - LRB103 27669 RLC 57233 b
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the cyclopropyl ring to any extent:
including, but not limited to, XLR11, UR144, FUB-144;
(60) 3-adamantoylindole with substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the adamantyl ring to any extent:
including, but not limited to, AB-001;
(61) N-(adamantyl)-indole-3-carboxamide with
substitution at the nitrogen atom of the indole ring by
alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl halide,
1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the adamantyl ring to any extent:
including, but not limited to, APICA/2NE-1, STS-135;
(62) N-(adamantyl)-indazole-3-carboxamide with
substitution at a nitrogen atom of the indazole ring by
alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl halide,
1-(N-methyl-2-piperidinyl)methyl, or

SB2089 - 16 - LRB103 27669 RLC 57233 b
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent, whether or not
substituted on the adamantyl ring to any extent:
including, but not limited to, AKB48, 5F-AKB48;
(63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
with substitution at the nitrogen atom of the indole ring
by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl halide,
1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the quinoline ring to any extent:
including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
(64) 3-(1-naphthoyl)indazole with substitution at the
nitrogen atom of the indazole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent, whether or not
substituted on the naphthyl ring to any extent: including,
but not limited to, THJ-018, THJ-2201;
(65) 2-(1-naphthoyl)benzimidazole with substitution
at the nitrogen atom of the benzimidazole ring by alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl halide,
1-(N-methyl-2-piperidinyl)methyl, or

SB2089 - 17 - LRB103 27669 RLC 57233 b
2-(4-morpholinyl)ethyl, whether or not further substituted
on the benzimidazole ring to any extent, whether or not
substituted on the naphthyl ring to any extent: including,
but not limited to, FUBIMINA;
(66)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
3-carboxamide with substitution on the nitrogen atom of
the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
(67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
indazole-3-carboxamide with substitution on the nitrogen
atom of the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, ADB-PINACA, ADB-FUBINACA;
(68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
indole-3-carboxamide with substitution on the nitrogen
atom of the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or

SB2089 - 18 - LRB103 27669 RLC 57233 b
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent: including, but not
limited to, ADBICA, 5F-ADBICA;
(69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
3-carboxamide with substitution on the nitrogen atom of
the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent: including, but not
limited to, ABICA, 5F-ABICA;
(70) Methyl 2-(1H-indazole-3-carboxamido)-3-
methylbutanoate with substitution on the nitrogen atom of
the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, AMB, 5F-AMB;
(71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
dimethylbutanoate with substitution on the nitrogen atom
of the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not

SB2089 - 19 - LRB103 27669 RLC 57233 b
limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
(72) Methyl 2-(1H-indole-3-carboxamido)-3-
methylbutanoate with substitution on the nitrogen atom of
the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, MMB018, MMB2201, and AMB-CHMICA;
(73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
dimethylbutanoate with substitution on the nitrogen atom
of the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, MDMB-CHMICA;
(74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
indazole-3-carboxamide with substitution on the nitrogen
atom of the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
(75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-

SB2089 - 20 - LRB103 27669 RLC 57233 b
3-carboxamide with substitution on the nitrogen atom of
the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, APP-PICA and 5-fluoro-APP-PICA;
(76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
4-AcO-DMT;
(77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
name 5-MeO-MIPT;
(78) 4-hydroxy Diethyltryptamine (4-HO-DET);
(79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
(80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
(81) 4-hydroxy-N-methyl-N-isopropyltryptamine
(4-HO-MiPT);
(82) Fluorophenylpiperazine;
(83) Methoxetamine;
(84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
ethcathinone).
(e) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a depressant effect on the central nervous
system, including its salts, isomers, and salts of isomers
whenever the existence of such salts, isomers, and salts of

SB2089 - 21 - LRB103 27669 RLC 57233 b
isomers is possible within the specific chemical designation:
(1) mecloqualone;
(2) methaqualone; and
(3) gamma hydroxybutyric acid; and
(4) xylazine.
(f) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system, including its salts, isomers, and salts of isomers:
(1) Fenethylline;
(2) N-ethylamphetamine;
(3) Aminorex (some other names:
2-amino-5-phenyl-2-oxazoline; aminoxaphen;
4-5-dihydro-5-phenyl-2-oxazolamine) and its
salts, optical isomers, and salts of optical isomers;
(4) Methcathinone (some other names:
2-methylamino-1-phenylpropan-1-one;
Ephedrone; 2-(methylamino)-propiophenone;
alpha-(methylamino)propiophenone; N-methylcathinone;
methycathinone; Monomethylpropion; UR 1431) and its
salts, optical isomers, and salts of optical isomers;
(5) Cathinone (some trade or other names:
2-aminopropiophenone; alpha-aminopropiophenone;
2-amino-1-phenyl-propanone; norephedrone);
(6) N,N-dimethylamphetamine (also known as:

SB2089 - 22 - LRB103 27669 RLC 57233 b
N,N-alpha-trimethyl-benzeneethanamine;
N,N-alpha-trimethylphenethylamine);
(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
(8) 3,4-Methylenedioxypyrovalerone (MDPV);
(9) Halogenated amphetamines and
methamphetamines - any compound derived from either
amphetamine or methamphetamine through the substitution
of a halogen on the phenyl ring, including, but not
limited to, 2-fluoroamphetamine, 3-
fluoroamphetamine and 4-fluoroamphetamine;
(10) Aminopropylbenzofuran (APB):
including 4-(2-Aminopropyl) benzofuran, 5-
(2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
benzofuran, and 7-(2-Aminopropyl) benzofuran;
(11) Aminopropyldihydrobenzofuran (APDB):
including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
(12) Methylaminopropylbenzofuran
(MAPB): including 4-(2-methylaminopropyl)
benzofuran, 5-(2-methylaminopropyl)benzofuran,
6-(2-methylaminopropyl)benzofuran
and 7-(2-methylaminopropyl)benzofuran.
(g) Temporary listing of substances subject to emergency

SB2089 - 23 - LRB103 27669 RLC 57233 b
scheduling. Any material, compound, mixture, or preparation
that contains any quantity of the following substances:
(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
(benzylfentanyl), its optical isomers, isomers, salts, and
salts of isomers;
(2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
phenylpropanamide (thenylfentanyl), its optical isomers,
salts, and salts of isomers.
(h) Synthetic cathinones. Unless specifically excepted,
any chemical compound which is not approved by the United
States Food and Drug Administration or, if approved, is not
dispensed or possessed in accordance with State or federal
law, not including bupropion, structurally derived from
2-aminopropan-1-one by substitution at the 1-position with
either phenyl, naphthyl, or thiophene ring systems, whether or
not the compound is further modified in one or more of the
following ways:
(1) by substitution in the ring system to any extent
with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
halide substituents, whether or not further substituted in
the ring system by one or more other univalent
substituents. Examples of this class include, but are not
limited to, 3,4-Methylenedioxycathinone (bk-MDA);
(2) by substitution at the 3-position with an acyclic
alkyl substituent. Examples of this class include, but are
not limited to, 2-methylamino-1-phenylbutan-1-one

SB2089 - 24 - LRB103 27669 RLC 57233 b
(buphedrone); or
(3) by substitution at the 2-amino nitrogen atom with
alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
inclusion of the 2-amino nitrogen atom in a cyclic
structure. Examples of this class include, but are not
limited to, Dimethylcathinone, Ethcathinone, and
a-Pyrrolidinopropiophenone (a-PPP); or
Any other synthetic cathinone which is not approved by the
United States Food and Drug Administration or, if approved, is
not dispensed or possessed in accordance with State or federal
law.
(i) Synthetic cannabinoids or piperazines. Any synthetic
cannabinoid or piperazine which is not approved by the United
States Food and Drug Administration or, if approved, which is
not dispensed or possessed in accordance with State and
federal law.
(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
8-14-18.)
(720 ILCS 570/401) (from Ch. 56 1/2, par. 1401)
Sec. 401. Manufacture or delivery, or possession with
intent to manufacture or deliver, a controlled substance, a
counterfeit substance, or controlled substance analog. Except
as authorized by this Act, it is unlawful for any person
knowingly to manufacture or deliver, or possess with intent to

SB2089 - 25 - LRB103 27669 RLC 57233 b
manufacture or deliver, a controlled substance other than
methamphetamine and other than bath salts as defined in the
Bath Salts Prohibition Act sold or offered for sale in a retail
mercantile establishment as defined in Section 16-0.1 of the
Criminal Code of 2012, a counterfeit substance, or a
controlled substance analog. A violation of this Act with
respect to each of the controlled substances listed herein
constitutes a single and separate violation of this Act. For
purposes of this Section, "controlled substance analog" or
"analog" means a substance, other than a controlled substance,
which is not approved by the United States Food and Drug
Administration or, if approved, is not dispensed or possessed
in accordance with State or federal law, and that has a
chemical structure substantially similar to that of a
controlled substance in Schedule I or II, or that was
specifically designed to produce an effect substantially
similar to that of a controlled substance in Schedule I or II.
Examples of chemical classes in which controlled substance
analogs are found include, but are not limited to, the
following: phenethylamines, N-substituted piperidines,
morphinans, ecgonines, quinazolinones, substituted indoles,
and arylcycloalkylamines. For purposes of this Act, a
controlled substance analog shall be treated in the same
manner as the controlled substance to which it is
substantially similar.
(a) Any person who violates this Section with respect to

SB2089 - 26 - LRB103 27669 RLC 57233 b
the following amounts of controlled or counterfeit substances
or controlled substance analogs, notwithstanding any of the
provisions of subsections (c), (d), (e), (f), (g) or (h) to the
contrary, is guilty of a Class X felony and shall be sentenced
to a term of imprisonment as provided in this subsection (a)
and fined as provided in subsection (b):
(1)(A) not less than 6 years and not more than 30 years
with respect to 15 grams or more but less than 100 grams of
a substance containing heroin, or an analog thereof;
(B) not less than 9 years and not more than 40 years
with respect to 100 grams or more but less than 400 grams
of a substance containing heroin, or an analog thereof;
(C) not less than 12 years and not more than 50 years
with respect to 400 grams or more but less than 900 grams
of a substance containing heroin, or an analog thereof;
(D) not less than 15 years and not more than 60 years
with respect to 900 grams or more of any substance
containing heroin, or an analog thereof;
(1.5)(A) not less than 6 years and not more than 30
years with respect to 15 grams or more but less than 100
grams of a substance containing fentanyl or xylazine, or
an analog thereof;
(B) not less than 9 years and not more than 40 years
with respect to 100 grams or more but less than 400 grams
of a substance containing fentanyl or xylazine, or an
analog thereof;

SB2089 - 27 - LRB103 27669 RLC 57233 b
(C) not less than 12 years and not more than 50 years
with respect to 400 grams or more but less than 900 grams
of a substance containing fentanyl or xylazine, or an
analog thereof;
(D) not less than 15 years and not more than 60 years
with respect to 900 grams or more of a substance
containing fentanyl or xylazine, or an analog thereof;
(2)(A) not less than 6 years and not more than 30 years
with respect to 15 grams or more but less than 100 grams of
a substance containing cocaine, or an analog thereof;
(B) not less than 9 years and not more than 40 years
with respect to 100 grams or more but less than 400 grams
of a substance containing cocaine, or an analog thereof;
(C) not less than 12 years and not more than 50 years
with respect to 400 grams or more but less than 900 grams
of a substance containing cocaine, or an analog thereof;
(D) not less than 15 years and not more than 60 years
with respect to 900 grams or more of any substance
containing cocaine, or an analog thereof;
(3)(A) not less than 6 years and not more than 30 years
with respect to 15 grams or more but less than 100 grams of
a substance containing morphine, or an analog thereof;
(B) not less than 9 years and not more than 40 years
with respect to 100 grams or more but less than 400 grams
of a substance containing morphine, or an analog thereof;
(C) not less than 12 years and not more than 50 years

SB2089 - 28 - LRB103 27669 RLC 57233 b
with respect to 400 grams or more but less than 900 grams
of a substance containing morphine, or an analog thereof;
(D) not less than 15 years and not more than 60 years
with respect to 900 grams or more of a substance
containing morphine, or an analog thereof;
(4) 200 grams or more of any substance containing
peyote, or an analog thereof;
(5) 200 grams or more of any substance containing a
derivative of barbituric acid or any of the salts of a
derivative of barbituric acid, or an analog thereof;
(6) 200 grams or more of any substance containing
amphetamine or any salt of an optical isomer of
amphetamine, or an analog thereof;
(6.5) (blank);
(6.6) (blank);
(7)(A) not less than 6 years and not more than 30 years
with respect to: (i) 15 grams or more but less than 100
grams of a substance containing lysergic acid diethylamide
(LSD), or an analog thereof, or (ii) 15 or more objects or
15 or more segregated parts of an object or objects but
less than 200 objects or 200 segregated parts of an object
or objects containing in them or having upon them any
amounts of any substance containing lysergic acid
diethylamide (LSD), or an analog thereof;
(B) not less than 9 years and not more than 40 years
with respect to: (i) 100 grams or more but less than 400

SB2089 - 29 - LRB103 27669 RLC 57233 b
grams of a substance containing lysergic acid diethylamide
(LSD), or an analog thereof, or (ii) 200 or more objects or
200 or more segregated parts of an object or objects but
less than 600 objects or less than 600 segregated parts of
an object or objects containing in them or having upon
them any amount of any substance containing lysergic acid
diethylamide (LSD), or an analog thereof;
(C) not less than 12 years and not more than 50 years
with respect to: (i) 400 grams or more but less than 900
grams of a substance containing lysergic acid diethylamide
(LSD), or an analog thereof, or (ii) 600 or more objects or
600 or more segregated parts of an object or objects but
less than 1500 objects or 1500 segregated parts of an
object or objects containing in them or having upon them
any amount of any substance containing lysergic acid
diethylamide (LSD), or an analog thereof;
(D) not less than 15 years and not more than 60 years
with respect to: (i) 900 grams or more of any substance
containing lysergic acid diethylamide (LSD), or an analog
thereof, or (ii) 1500 or more objects or 1500 or more
segregated parts of an object or objects containing in
them or having upon them any amount of a substance
containing lysergic acid diethylamide (LSD), or an analog
thereof;
(7.5)(A) not less than 6 years and not more than 30 years
with respect to: (i) 15 grams or more but less than 100

SB2089 - 30 - LRB103 27669 RLC 57233 b
grams of a substance listed in paragraph (1), (2), (2.1),
(2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
(26) of subsection (d) of Section 204, or an analog or
derivative thereof, or (ii) 15 or more pills, tablets,
caplets, capsules, or objects but less than 200 pills,
tablets, caplets, capsules, or objects containing in them
or having upon them any amounts of any substance listed in
paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
(20.1), (21), (25), or (26) of subsection (d) of Section
204, or an analog or derivative thereof;
(B) not less than 9 years and not more than 40 years
with respect to: (i) 100 grams or more but less than 400
grams of a substance listed in paragraph (1), (2), (2.1),
(2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
(26) of subsection (d) of Section 204, or an analog or
derivative thereof, or (ii) 200 or more pills, tablets,
caplets, capsules, or objects but less than 600 pills,
tablets, caplets, capsules, or objects containing in them
or having upon them any amount of any substance listed in
paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
(20.1), (21), (25), or (26) of subsection (d) of Section
204, or an analog or derivative thereof;
(C) not less than 12 years and not more than 50 years
with respect to: (i) 400 grams or more but less than 900
grams of a substance listed in paragraph (1), (2), (2.1),
(2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or

SB2089 - 31 - LRB103 27669 RLC 57233 b
(26) of subsection (d) of Section 204, or an analog or
derivative thereof, or (ii) 600 or more pills, tablets,
caplets, capsules, or objects but less than 1,500 pills,
tablets, caplets, capsules, or objects containing in them
or having upon them any amount of any substance listed in
paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
(20.1), (21), (25), or (26) of subsection (d) of Section
204, or an analog or derivative thereof;
(D) not less than 15 years and not more than 60 years
with respect to: (i) 900 grams or more of any substance
listed in paragraph (1), (2), (2.1), (2.2), (3), (14.1),
(19), (20), (20.1), (21), (25), or (26) of subsection (d)
of Section 204, or an analog or derivative thereof, or
(ii) 1,500 or more pills, tablets, caplets, capsules, or
objects containing in them or having upon them any amount
of a substance listed in paragraph (1), (2), (2.1), (2.2),
(3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
subsection (d) of Section 204, or an analog or derivative
thereof;
(8) 30 grams or more of any substance containing
pentazocine or any of the salts, isomers and salts of
isomers of pentazocine, or an analog thereof;
(9) 30 grams or more of any substance containing
methaqualone or any of the salts, isomers and salts of
isomers of methaqualone, or an analog thereof;
(10) 30 grams or more of any substance containing

SB2089 - 32 - LRB103 27669 RLC 57233 b
phencyclidine or any of the salts, isomers and salts of
isomers of phencyclidine (PCP), or an analog thereof;
(10.5) 30 grams or more of any substance containing
ketamine or any of the salts, isomers and salts of isomers
of ketamine, or an analog thereof;
(10.6) 100 grams or more of any substance containing
hydrocodone, or any of the salts, isomers and salts of
isomers of hydrocodone, or an analog thereof;
(10.7) (blank);
(10.8) 100 grams or more of any substance containing
dihydrocodeine, or any of the salts, isomers and salts of
isomers of dihydrocodeine, or an analog thereof;
(10.9) 100 grams or more of any substance containing
oxycodone, or any of the salts, isomers and salts of
isomers of oxycodone, or an analog thereof;
(11) 200 grams or more of any substance containing any
other controlled substance classified in Schedules I or
II, or an analog thereof, which is not otherwise included
in this subsection.
(b) Any person sentenced with respect to violations of
paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
involving 100 grams or more of the controlled substance named
therein, may in addition to the penalties provided therein, be
fined an amount not more than $500,000 or the full street value
of the controlled or counterfeit substance or controlled
substance analog, whichever is greater. The term "street

SB2089 - 33 - LRB103 27669 RLC 57233 b
value" shall have the meaning ascribed in Section 110-5 of the
Code of Criminal Procedure of 1963. Any person sentenced with
respect to any other provision of subsection (a), may in
addition to the penalties provided therein, be fined an amount
not to exceed $500,000.
(b-1) Excluding violations of this Act when the controlled
substance is fentanyl, any person sentenced to a term of
imprisonment with respect to violations of Section 401, 401.1,
405, 405.1, 405.2, or 407, when the substance containing the
controlled substance contains any amount of fentanyl, 3 years
shall be added to the term of imprisonment imposed by the
court, and the maximum sentence for the offense shall be
increased by 3 years.
(c) Any person who violates this Section with regard to
the following amounts of controlled or counterfeit substances
or controlled substance analogs, notwithstanding any of the
provisions of subsections (a), (b), (d), (e), (f), (g) or (h)
to the contrary, is guilty of a Class 1 felony. The fine for
violation of this subsection (c) shall not be more than
$250,000:
(1) 1 gram or more but less than 15 grams of any
substance containing heroin, or an analog thereof;
(1.5) 1 gram or more but less than 15 grams of any
substance containing fentanyl, or an analog thereof;
(2) 1 gram or more but less than 15 grams of any
substance containing cocaine, or an analog thereof;

SB2089 - 34 - LRB103 27669 RLC 57233 b
(2.5) 1 gram or more but less than 15 grams of any
substance containing xylazine, or an analog thereof;
(3) 10 grams or more but less than 15 grams of any
substance containing morphine, or an analog thereof;
(4) 50 grams or more but less than 200 grams of any
substance containing peyote, or an analog thereof;
(5) 50 grams or more but less than 200 grams of any
substance containing a derivative of barbituric acid or
any of the salts of a derivative of barbituric acid, or an
analog thereof;
(6) 50 grams or more but less than 200 grams of any
substance containing amphetamine or any salt of an optical
isomer of amphetamine, or an analog thereof;
(6.5) (blank);
(7)(i) 5 grams or more but less than 15 grams of any
substance containing lysergic acid diethylamide (LSD), or
an analog thereof, or (ii) more than 10 objects or more
than 10 segregated parts of an object or objects but less
than 15 objects or less than 15 segregated parts of an
object containing in them or having upon them any amount
of any substance containing lysergic acid diethylamide
(LSD), or an analog thereof;
(7.5)(i) 5 grams or more but less than 15 grams of any
substance listed in paragraph (1), (2), (2.1), (2.2), (3),
(14.1), (19), (20), (20.1), (21), (25), or (26) of
subsection (d) of Section 204, or an analog or derivative

SB2089 - 35 - LRB103 27669 RLC 57233 b
thereof, or (ii) more than 10 pills, tablets, caplets,
capsules, or objects but less than 15 pills, tablets,
caplets, capsules, or objects containing in them or having
upon them any amount of any substance listed in paragraph
(1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
(21), (25), or (26) of subsection (d) of Section 204, or an
analog or derivative thereof;
(8) 10 grams or more but less than 30 grams of any
substance containing pentazocine or any of the salts,
isomers and salts of isomers of pentazocine, or an analog
thereof;
(9) 10 grams or more but less than 30 grams of any
substance containing methaqualone or any of the salts,
isomers and salts of isomers of methaqualone, or an analog
thereof;
(10) 10 grams or more but less than 30 grams of any
substance containing phencyclidine or any of the salts,
isomers and salts of isomers of phencyclidine (PCP), or an
analog thereof;
(10.5) 10 grams or more but less than 30 grams of any
substance containing ketamine or any of the salts, isomers
and salts of isomers of ketamine, or an analog thereof;
(10.6) 50 grams or more but less than 100 grams of any
substance containing hydrocodone, or any of the salts,
isomers and salts of isomers of hydrocodone, or an analog
thereof;

SB2089 - 36 - LRB103 27669 RLC 57233 b
(10.7) (blank);
(10.8) 50 grams or more but less than 100 grams of any
substance containing dihydrocodeine, or any of the salts,
isomers and salts of isomers of dihydrocodeine, or an
analog thereof;
(10.9) 50 grams or more but less than 100 grams of any
substance containing oxycodone, or any of the salts,
isomers and salts of isomers of oxycodone, or an analog
thereof;
(11) 50 grams or more but less than 200 grams of any
substance containing a substance classified in Schedules I
or II, or an analog thereof, which is not otherwise
included in this subsection.
(c-5) (Blank).
(d) Any person who violates this Section with regard to
any other amount of a controlled or counterfeit substance
containing dihydrocodeine or classified in Schedules I or II,
or an analog thereof, which is (i) a narcotic drug, (ii)
lysergic acid diethylamide (LSD) or an analog thereof, (iii)
any substance containing amphetamine or fentanyl or xylazine
or any salt or optical isomer of amphetamine or fentanyl or
xylazine, or an analog thereof, or (iv) any substance
containing N-Benzylpiperazine (BZP) or any salt or optical
isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
guilty of a Class 2 felony. The fine for violation of this
subsection (d) shall not be more than $200,000.

SB2089 - 37 - LRB103 27669 RLC 57233 b
(d-5) (Blank).
(e) Any person who violates this Section with regard to
any other amount of a controlled substance other than
methamphetamine or counterfeit substance classified in
Schedule I or II, or an analog thereof, which substance is not
included under subsection (d) of this Section, is guilty of a
Class 3 felony. The fine for violation of this subsection (e)
shall not be more than $150,000.
(f) Any person who violates this Section with regard to
any other amount of a controlled or counterfeit substance
classified in Schedule III is guilty of a Class 3 felony. The
fine for violation of this subsection (f) shall not be more
than $125,000.
(g) Any person who violates this Section with regard to
any other amount of a controlled or counterfeit substance
classified in Schedule IV is guilty of a Class 3 felony. The
fine for violation of this subsection (g) shall not be more
than $100,000.
(h) Any person who violates this Section with regard to
any other amount of a controlled or counterfeit substance
classified in Schedule V is guilty of a Class 3 felony. The
fine for violation of this subsection (h) shall not be more
than $75,000.
(i) This Section does not apply to the manufacture,
possession or distribution of a substance in conformance with
the provisions of an approved new drug application or an

SB2089 - 38 - LRB103 27669 RLC 57233 b
exemption for investigational use within the meaning of
Section 505 of the Federal Food, Drug and Cosmetic Act.
(j) (Blank).
(Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17;
100-368, eff. 1-1-18.)